The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 18, 2005
Filed:
Nov. 27, 2002
Moussa B. H. Youdim, Tivon, IL;
John P. M. Finberg, Tivon, IL;
Ruth Levy, Tel-Aviv, IL;
Jeffrey Sterling, Jerusalem, IL;
David Lerner, Jerusalem, IL;
Haim Yellin, Ramat-Gan, IL;
Alex Veinberg, Rehovot, IL;
Moussa B. H. Youdim, Tivon, IL;
John P. M. Finberg, Tivon, IL;
Ruth Levy, Tel-Aviv, IL;
Jeffrey Sterling, Jerusalem, IL;
David Lerner, Jerusalem, IL;
Haim Yellin, Ramat-Gan, IL;
Alex Veinberg, Rehovot, IL;
Teva Pharmaceutical Industries, Ltd., Petach-Tikva, IL;
Technion Research and Development Foundation Ltd., Haifa, IL;
Abstract
The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an effective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.